financetom
Business
financetom
/
Business
/
US defense shares, government contractors fall after Trump efficiency picks
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US defense shares, government contractors fall after Trump efficiency picks
Nov 15, 2024 1:53 PM

NEW YORK (Reuters) - Shares of defense companies and government contractors were lower on Friday, extending recent losses amid uncertainty surrounding President-elect Donald Trump's proposed Department of Government Efficiency.

Trump, a Republican who won last week's election against Democratic Vice President Kamala Harris, this week named Elon Musk and former Republican presidential candidate Vivek Ramaswamy to co-lead the proposed efficiency department, an entity Trump indicated will operate outside the confines of government.

Among defense contractors, shares of General Dynamics ( GD ) fell 1.5% on Friday, while Lockheed Martin ( LMT ) was off 0.8% and Northrop Grumman ( NOC ) was down 1.3%.

The S&P 500 Aerospace & Defense index was down 0.6%.

Shares of government contractors also continued their recent slide on Friday, including Leidos Holdings ( LDOS ), which was down 4.4%; Science Applications International ( SAIC ), which was down 2.8%; and Booz Allen Hamilton ( BAH ), which fell 3%.

General Dynamics ( GD ) was down about 7% for the week, while Leidos ( LDOS ) fell 19%. Both stocks suffered their biggest weekly percentage drops in more than four years.

JP Morgan analysts wrote in a research note Thursday that the trigger for the decline in the government contractors' shares signals concern about the efficiency department "and how it may result in budget cuts and policy changes that reduce contractor earnings."

The Musk and Ramaswamy picks were among some others this week by Trump, including Robert F. Kennedy Jr. to lead the Department of Health and Human Services and Pete Hegseth to be secretary of defense.

"It's creating a lot of disruption and uncertainty with respect to industries that are subject to government regulation," said Rick Meckler, partner at Cherry Lane Investments, a family investment office in New Vernon, New Jersey.

"It's unclear how many of these selections will ultimately be approved ... but corporate America and investors in corporate America like a more certain path where they can value companies based on expected earnings and growth, and there are some radical selections here that could potentially lead to dramatic changes."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Leidos lifts annual profit forecast after third-quarter beat on resilient demand
Leidos lifts annual profit forecast after third-quarter beat on resilient demand
Nov 4, 2025
(Reuters) -Defense contractor Leidos Holdings ( LDOS ) lifted its annual profit forecast on Tuesday, backed by resilient demand for its munitions. Its shares rose about 2.7% before the bell. Leidos ( LDOS ) and its competitors have benefited from the global rise in defense spending amid the Russia-Ukraine war and unabated tensions in the Middle East. It sees annual...
Norwegian Cruise Line misses quarterly revenue estimates
Norwegian Cruise Line misses quarterly revenue estimates
Nov 4, 2025
Nov 4 (Reuters) - Norwegian Cruise Line Holdings ( NCLH ) missed third-quarter revenue expectations on Tuesday on subdued consumer appetite for sea-based vacations following years of strength. The cruise operator's quarterly revenue rose 5% to $2.94 billion, compared with analysts' expectation of $3.02 billion, according data compiled by LSEG. ...
Compass Pathways to expedite launch timing of its experimental depression therapy
Compass Pathways to expedite launch timing of its experimental depression therapy
Nov 4, 2025
Nov 4 (Reuters) - Drug developer Compass Pathways ( CMPS ) said on Tuesday it is pulling forward the expected launch timing of its experimental psilocybin-based depression therapy by 9 to 12 months. The decision follows the completion of enrollment for a late-stage study for the psychedelic-based therapy, COMP360, as well as a positive meeting with the U.S. Food and...
Henry Schein Q3 Adjusted Earnings, Revenue Rise; 2025 EPS Guidance Raised
Henry Schein Q3 Adjusted Earnings, Revenue Rise; 2025 EPS Guidance Raised
Nov 4, 2025
06:30 AM EST, 11/04/2025 (MT Newswires) -- Henry Schein (HSIC) reported Q3 adjusted earnings Tuesday of $1.38 per diluted share, up from $1.22 a year earlier. Analysts surveyed by FactSet expected $1.28. Revenue for the three months ended Sept. 27 was $3.34 billion, up from $3.17 billion a year earlier. Analysts polled by FactSet expected $3.28 billion. The company raised...
Copyright 2023-2026 - www.financetom.com All Rights Reserved